Variational AI Joins Agora Open Science Trust to Advance PRMT6 Inhibitors for SBMA
Variational AI is proud to announce its participation in a new open science drug discovery initiative led by Agora Open Science Trust. The project is focused on optimizing the potency and selectivity of lead inhibitors targeting PRMT6, a Type I protein arginine methyltransferase implicated in the pathogenesis of Spinal Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder.
Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Variational AI is proud to announce that it has been named Emerging Company of the Year – Biotech by Life Sciences BC. This award highlights Variational AI’s innovation in developing Enki, a generative AI foundation model that delivers novel and selective lead compounds to pharmaceutical and biotechnology companies.
Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic Dermatitis
Variational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis.
Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies
Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™Lead Generator to discover first-in-class cancer drugs.
